Humanigen (KBIO) Receiving Somewhat Favorable News Coverage, Report Finds
News headlines about Humanigen (NASDAQ:KBIO) have trended somewhat positive this week, Accern reports. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Humanigen earned a coverage optimism score of 0.10 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 47.0588051715492 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Humanigen (NASDAQ KBIO) opened at 2.19 on Friday. The company’s market cap is $32.80 million. Humanigen has a one year low of $1.50 and a one year high of $4.75. The stock has a 50 day moving average of $1.84 and a 200 day moving average of $2.45.
WARNING: This piece was originally posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://theolympiareport.com/2017/08/27/humanigen-kbio-receiving-somewhat-favorable-news-coverage-report-finds.html.
Humanigen, Inc, formerly KaloBios Pharmaceuticals, Inc, is a biopharmaceutical company. The Company focuses on developing medicines for patients with neglected and rare diseases, with an ancillary focus on pediatric conditions. The Company’s product candidate is benznidazole for the treatment of Chagas disease, a parasitic illness that can lead to long-term heart, intestinal and neurological problems.
Receive News & Ratings for Humanigen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humanigen Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.